Back to my company list

Genome Biologics

The AI engine Fit Assessment

Beta

Genome Biologics effectively leverages machine learning for drug development, pattern discovery, and the expansion of novel therapeutics, including drug repurposing.

Blurb

Genome Biologics identifies novel tissue-specific RNAi therapies targeting the transcriptome of cardiovascular and cardiometabolic disease

HQ Location

Germany

Founded

2016

Employees

5

Total funding raised

$20.20M

Last Funding Event

Venture - Series Unknown, $17.33M, October 6, 2021

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Drug Repurposing

Operator of a Biotherapeutics platform intended to facilitate efficient and ethical drug development and positioning. The company's platform leverages the power of AI-based machine learning with a transformative single-cell in vitro and in vivo transgenesis to identify new compounds or to repurpose known compounds for the treatment of cardiovascular and cardiometabolic and cancer, enabling medical researchers to reduce the cost, time and ethical burden of preclinical research.